GEA
IRWD icon

Glen Eagle Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Glen Eagle Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-156
Closed -$1.64K – 1101
2023
Q1 		$1.64K Sell
156
-296
-65% -$3.32K ﹤0.01% 885
2022
Q4 		$5.6K Hold
452
– – ﹤0.01% 698
2022
Q3 		$4.68K Buy
+452
New +$5.12K ﹤0.01% 720
2017
Q3 		– Sell
-12
Closed -$189 – 645
2017
Q2 		$189 Hold
12
– – ﹤0.01% 578
2017
Q1 		$171 Buy
+12
New +$164 ﹤0.01% 543

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Glen Eagle Advisors's IRWD Position: Q2 2023 in Review

Glen Eagle Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2023, closing a stake of 156 shares — an estimated $1.64K sold.

Glen Eagle Advisors first reported a position in IRWD in Q1 2017 and held it in 5 quarters. The position peaked at $5.6K in Q4 2022. 252 funds tracked by Wall St. Rank hold IRWD as of Q2 2023.

  • Glen Eagle Advisors reported no remaining Ironwood Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Glen Eagle Advisors sold 156 Ironwood Pharmaceuticals shares in Q2 2023, an estimated $1.64K.
  • Glen Eagle Advisors first reported a position in Ironwood Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Glen Eagle Advisors's Ironwood Pharmaceuticals position peaked at $5.6K in Q4 2022.
  • 252 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2023.

Based on Glen Eagle Advisors's 13F filing for Q2 2023, filed 13 Aug 2024.